UBS Group
TVRD

UBS Group’s Tvardi Therapeutics TVRD Stock Holding History

UBS Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,175
Closed -$1.21M – 8058
2017
Q2 		$1.21M Buy
+2,175
New +$1.38M ﹤0.01% 3451

Other funds holding TVRD

SPC
Slate Path Capital New York $7.22B AUM 110.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AFG
American Financial Group Cincinnati, Ohio $284M AUM 12.01% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS Group's TVRD Position: Q2 2026 in Review

UBS Group increased its Tvardi Therapeutics (TVRD) stake by 120% in Q2 2026, buying an estimated $190K and bringing the position to 111,133 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #6760.

UBS Group first reported a position in TVRD in Q4 2014 and has held it in 47 quarters since. The position peaked at $2.64M in Q4 2018. 57 funds tracked by Wall St. Rank hold TVRD as of Q2 2026.

  • UBS Group held 111,133 shares of Tvardi Therapeutics worth $211K as of Q2 2026.
  • UBS Group bought 60,679 Tvardi Therapeutics shares in Q2 2026, an estimated $190K.
  • Tvardi Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #6760 holding.
  • UBS Group first reported a position in Tvardi Therapeutics in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Tvardi Therapeutics position peaked at $2.64M in Q4 2018.
  • 57 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.